Allena Pharmaceuticals, Inc. ROE

ROE of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including ROE growth rates and interactive chart. ROE is expressed as a percentage and can be calculated for any company if net income and equity are both positive numbers. Net income is calculated before dividends paid to common shareholders and after dividends to preferred shareholders and interest to lenders. A company with average equity of $10 million and earnings of $2 milion will have a ROE of 20%.


Highlights and Quick Summary

  • Annual ROE for 2021 was -234.88% (a 42.19% increase from previous year)
  • Annual ROE for 2020 was -165.19% (a 16.3% increase from previous year)
  • Annual ROE for 2019 was -142.04% (a 163.62% increase from previous year)
  • Twelve month ROE ending March 31, 2022 was -278.14% (a 18.42% increase compared to previous quarter)
  • Twelve month trailing ROE decreased by -2.92% year-over-year
Trailing ROE for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
-278.14% -234.88% -219.67% -286.5%
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical ROE of Allena Pharmaceuticals, Inc.

Most recent ROEof ALNA including historical data for past 10 years.

Interactive Chart of ROE of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. ROE for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 -234.88%
2020 -165.19%
2019 -142.04%
2018 -53.88%
2017 -184.02%
2016 52.01%
2015 30.23%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.